Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming

Paul W. Burridge; Gordon Keller; Joseph D. Gold; Joseph C. Wu

doi:10.1016/j.stem.2011.12.013

Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming

Paul W. Burridge, Gordon Keller, Joseph D. Gold, Joseph C. Wu^*

^*Corresponding author for this work

Pharmacology

Research output: Contribution to journal › Review article › peer-review

539 Scopus citations

Abstract

Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.

Original language	English (US)
Pages (from-to)	16-28
Number of pages	13
Journal	Cell stem cell
Volume	10
Issue number	1
DOIs	https://doi.org/10.1016/j.stem.2011.12.013
State	Published - Jan 6 2012

Funding

We would like to acknowledge funding support from the NIH New Innovator Award DP2OD004437, RC1AG036142, R33HL089027, the California Institute of Regenerative Medicine RB3-05219, and the Burroughs Wellcome Foundation Career Award for Medical Scientists (J.C.W.). Due to space limitations, we are unable to include all of the important papers relevant to induced pluripotent stem cell derivation and application; we apologize to those investigators whose work was omitted here. Joseph Gold is an employee of Geron Corporation.

ASJC Scopus subject areas

Genetics
Molecular Medicine
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.stem.2011.12.013

Cite this

@article{3a8eb58d2e10454aaf5dc4fa62fc06d5,

title = "Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming",

abstract = "Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.",

author = "Burridge, {Paul W.} and Gordon Keller and Gold, {Joseph D.} and Wu, {Joseph C.}",

note = "Funding Information: We would like to acknowledge funding support from the NIH New Innovator Award DP2OD004437, RC1AG036142, R33HL089027, the California Institute of Regenerative Medicine RB3-05219, and the Burroughs Wellcome Foundation Career Award for Medical Scientists (J.C.W.). Due to space limitations, we are unable to include all of the important papers relevant to induced pluripotent stem cell derivation and application; we apologize to those investigators whose work was omitted here. Joseph Gold is an employee of Geron Corporation.",

year = "2012",

month = jan,

day = "6",

doi = "10.1016/j.stem.2011.12.013",

language = "English (US)",

volume = "10",

pages = "16--28",

journal = "Cell stem cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Production of de novo cardiomyocytes

T2 - Human pluripotent stem cell differentiation and direct reprogramming

AU - Burridge, Paul W.

AU - Keller, Gordon

AU - Gold, Joseph D.

AU - Wu, Joseph C.

N1 - Funding Information: We would like to acknowledge funding support from the NIH New Innovator Award DP2OD004437, RC1AG036142, R33HL089027, the California Institute of Regenerative Medicine RB3-05219, and the Burroughs Wellcome Foundation Career Award for Medical Scientists (J.C.W.). Due to space limitations, we are unable to include all of the important papers relevant to induced pluripotent stem cell derivation and application; we apologize to those investigators whose work was omitted here. Joseph Gold is an employee of Geron Corporation.

PY - 2012/1/6

Y1 - 2012/1/6

N2 - Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.

AB - Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.

UR - http://www.scopus.com/inward/record.url?scp=84862907693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862907693&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2011.12.013

DO - 10.1016/j.stem.2011.12.013

M3 - Review article

C2 - 22226352

AN - SCOPUS:84862907693

SN - 1934-5909

VL - 10

SP - 16

EP - 28

JO - Cell stem cell

JF - Cell stem cell

IS - 1

ER -

Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this